ABT-199 + bortezomib + dexamethasone
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Nov 19, 2012 โ Jul 16, 2019
NCT ID
NCT01794507About ABT-199 + bortezomib + dexamethasone
ABT-199 + bortezomib + dexamethasone is a phase 1 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01794507. Target conditions include Relapsed/Refractory Multiple Myeloma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01794507 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma